<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002544</url>
  </required_header>
  <id_info>
    <org_study_id>GER-AIO-01/92</org_study_id>
    <secondary_id>CDR0000063279</secondary_id>
    <secondary_id>EU-93011</secondary_id>
    <nct_id>NCT00002544</nct_id>
  </id_info>
  <brief_title>Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. It is not yet known if mitoxantrone is more effective with or
      without docetaxel.

      PURPOSE: Randomized phase III trial to compare the effectiveness of mitoxantrone with or
      without docetaxel in treating women who have metastatic breast cancer with a poor prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the survival and quality of life scores (composed of time to progression, WHO
           performance status, subjective patient evaluation, and subjective adverse event profile)
           among women with metastatic breast cancer of unfavorable prognosis treated with
           mitoxantrone vs mitoxantrone plus docetaxel as first-line chemotherapy for metastatic
           disease.

        -  Compare the remission rate, time to remission, remission duration, time to best
           response, objective adverse events, and patient acceptance of treatment on these 2
           regimens.

        -  Investigate which prognostic subgroups of women benefit from treatment.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age,
      treatment center, disease free interval (no more than 18 months vs more than 18 months),
      hormone receptor status (positive or unknown vs negative), prior adjuvant therapy with
      anthracyclines (yes vs no), presence of liver metastases (liver involvement as a single organ
      vs liver plus other organ involvement vs no liver involvement), and presence of lung
      metastases (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive mitoxantrone IV on day 1. Treatment repeats every 3 weeks until
           disease progression, unacceptable toxicity, or maximum cumulative dose. Patients who
           achieve complete response receive 2 additional courses.

        -  Arm II: Patients receive mitoxantrone IV plus docetaxel IV over 1 hour on day 1.
           Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease
           progression or unacceptable toxicity.

      At relapse, reinduction with the original regimen is attempted. Following a second complete
      response, 2 additional courses of consolidative treatment are given, and patients are then
      followed off treatment.

      Quality of life is assessed periodically.

      PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1993</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven metastatic breast cancer of poor prognosis, defined by any of
             the following characteristics:

               -  Patient aged 35 or under

               -  Liver metastases

               -  Lung metastases combined with other disease manifestations

               -  Lung metastases without other disease manifestations but with a disease free
                  interval of no more than 18 months

          -  Indication for chemotherapy documented by either:

               -  Hormone receptor negativity OR

               -  Hormone resistant disease

          -  Measurable metastatic disease required

               -  Nonmeasurable disease includes:

                    -  Metastases verified only histologically

                    -  Tumor parameters not precisely measurable (e.g., bone marrow involvement,
                       lymphangitic disease)

          -  No CNS metastasis or bone marrow carcinomatosis

          -  Hormone receptor status:

               -  Receptor status known

        PATIENT CHARACTERISTICS:

        Age:

          -  80 and under

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  WBC greater than 4,000/mm^3

          -  Absolute granulocyte count greater than 2,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)

          -  Alkaline phosphatase no greater than 6 times ULN

          -  SGOT and/or SGPT no greater than 3 times ULN

        Renal:

          -  Creatinine no greater than 1.15 times ULN

        Cardiovascular:

          -  No uncontrolled hypertension

          -  No congestive heart failure within the past 6 months

          -  No myocardial infarction within the past 6 months

        Other:

          -  Fertile patients must use effective contraception

          -  No acute or chronic infection

          -  No second primary tumor

          -  No other serious illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent biologic therapy

        Chemotherapy:

          -  No prior chemotherapy for metastatic disease

          -  Greater than 1 year since prior adjuvant chemotherapy

          -  No prior anthracycline or anthraquinone

        Endocrine therapy:

          -  Hormone resistant disease required of receptor positive patients

          -  No concurrent endocrine therapy

        Radiotherapy:

          -  No prior mediastinal irradiation

          -  Adjuvant irradiation of parasternal nodes eligible

          -  No prior irradiation to more than 25% of bone marrow

          -  No concurrent irradiation of sole measurable lesion

        Surgery:

          -  Not specified

        Other:

          -  No concurrent anticoagulant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Else G. Heidemann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Diakonie Klinikum Stuttgart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diakonissen-Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Heidemann E, Souchon R, Stoger H, et al.: First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer: a prospective randomized multicenter clinical trial. Onkologie 23(1): 54-59, 2000.</citation>
  </reference>
  <reference>
    <citation>Heidemann E, Stoeger H, Souchon R, et al.: Balance of time to progression, quality of life, and overall survival: more gain from treatment in single agent treatment with mitoxantrone (N) than with the combination of fluorouracil, epirubicin, cyclophosphamide (FEC). Results of a multicenter randomized trial in high risk metastatic breast cancer (MBC). [Abstract] Proceedings of the American Society of Clinical Oncology A-284, 74a, 2000.</citation>
  </reference>
  <reference>
    <citation>Loibl S, von Minckwitz G, Souchon R, et al.: Phase I/II study with mitoxantrone (N) vs. NDOC in patients with high risk locally advanced or metastatic breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A512, 1999.</citation>
  </reference>
  <results_reference>
    <citation>Heidemann E, Stoeger H, Souchon R, Hirschmann WD, Bodenstein H, Oberhoff C, Fischer JT, Schulze M, Clemens M, Andreesen R, Mahlke M, KÃ¶nig M, Scharl A, Fehnle K, Kaufmann M. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol. 2002 Nov;13(11):1717-29.</citation>
    <PMID>12419743</PMID>
  </results_reference>
  <verification_date>April 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

